[HTML][HTML] Monkeypox: epidemiology, pathogenesis, treatment and prevention
Y Huang, L Mu, W Wang - Signal Transduction and Targeted Therapy, 2022 - nature.com
Monkeypox is a zoonotic disease that was once endemic in west and central Africa caused
by monkeypox virus. However, cases recently have been confirmed in many nonendemic …
by monkeypox virus. However, cases recently have been confirmed in many nonendemic …
[HTML][HTML] Monkeypox: a comprehensive review
The 2022 multi-country monkeypox outbreak in humans has brought new public health
adversity on top of the ongoing coronavirus disease 2019 (COVID-19) pandemic. The …
adversity on top of the ongoing coronavirus disease 2019 (COVID-19) pandemic. The …
Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model
CL Hutson, AV Kondas, MR Mauldin, JB Doty… - MSphere, 2021 - Am Soc Microbiol
Smallpox, caused by Variola virus (VARV), was eradicated in 1980; however, VARV
bioterrorist threats still exist, necessitating readily available therapeutics. Current …
bioterrorist threats still exist, necessitating readily available therapeutics. Current …
Antivirals with activity against mpox: a clinically oriented review
EA Siegrist, J Sassine - Clinical infectious diseases, 2023 - academic.oup.com
Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still
cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with …
cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with …
[HTML][HTML] A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell …
FM Marty, DJ Winston, RF Chemaly, KM Mullane… - Biology of Blood and …, 2019 - Elsevier
Cytomegalovirus (CMV) infection is a common complication of allogeneic hematopoietic cell
transplantation (HCT). In this trial, we randomized adult CMV-seropositive HCT recipients …
transplantation (HCT). In this trial, we randomized adult CMV-seropositive HCT recipients …
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19
S Jockusch, C Tao, X Li, TK Anderson, M Chien… - Antiviral research, 2020 - Elsevier
Abstract SARS-CoV-2, a member of the coronavirus family, is responsible for the current
COVID-19 worldwide pandemic. We previously demonstrated that five nucleotide analogues …
COVID-19 worldwide pandemic. We previously demonstrated that five nucleotide analogues …
Benefit-risk assessment for brincidofovir for the treatment of smallpox: US Food and Drug Administration's Evaluation
K Chan-Tack, P Harrington, T Bensman, SY Choi… - Antiviral research, 2021 - Elsevier
The development and approval of brincidofovir for the treatment of smallpox, a disease that
was eradicated from the world over 40 years ago, has resulted in the second antiviral …
was eradicated from the world over 40 years ago, has resulted in the second antiviral …
[HTML][HTML] Human monkeypox: a comparison of the characteristics of the new epidemic to the endemic disease
S Sukhdeo, S Mishra, S Walmsley - BMC infectious diseases, 2022 - Springer
In May 2022, a new global outbreak of mpox (formerly, human monkeypox) emerged that
was declared a public health emergency of international concern by the World Health …
was declared a public health emergency of international concern by the World Health …
Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead …
MAM Subbaiah, J Rautio, NA Meanwell - Chemical Society Reviews, 2024 - pubs.rsc.org
The delivery of a drug to a specific organ or tissue at an efficacious concentration is the
pharmacokinetic (PK) hallmark of promoting effective pharmacological action at a target site …
pharmacokinetic (PK) hallmark of promoting effective pharmacological action at a target site …
Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox
G Chittick, M Morrison, T Brundage, WG Nichols - Antiviral research, 2017 - Elsevier
Abstract Brincidofovir (BCV, CMX001) is an orally available, long-acting, broad-spectrum
antiviral that has been evaluated in healthy subjects in Phase I studies and in hematopoietic …
antiviral that has been evaluated in healthy subjects in Phase I studies and in hematopoietic …